RESUMO
BACKGROUND: There have been many reports on the use of morphine for postoperative pain relief in children, but the use of fentanyl for this purpose has not frequently been described. We clarified the details of side effects exhibited in children who had received continuous fentanyl infusion for postoperative pain relief METHODS: The subjects are 1,166 children aged between 0 and 14 years who underwent continuous fentanyl infusion for postoperative pain relief within the previous 4 years. Fentanyl was administered at a dose of 0.5 or 1.0 µg x kg(-1) x hr(-1), and with continuous use of pulse oximeter, the pulse rate, SpO2, respiratory rate, BP, sedation score, and presence/absence of nausea/vomiting were recorded every 2 hours. The frequencies of side effects were retrospectively examined. RESULTS: Severe side effects, including respiratory depression, for which mask ventilation or tracheal intubation was required were observed in 0.77% of cases. No subjects died or developed permanent sequelae. Nausea/vomiting occurred in 25.4% of cases. CONCLUSIONS: Using monitoring systems that facilitate the early detection of and intervention in respiratory depression, we can safely administer continuous fentanyl infusion for postoperative pain relief in children. It is necessary to adopt countermeasures against nausea/vomiting.
Assuntos
Anestésicos Intravenosos/efeitos adversos , Fentanila/efeitos adversos , Dor Pós-Operatória/tratamento farmacológico , Adolescente , Anestésicos Intravenosos/uso terapêutico , Criança , Pré-Escolar , Fentanila/uso terapêutico , Humanos , Lactente , Náusea/induzido quimicamente , Estudos Retrospectivos , Vômito/induzido quimicamenteRESUMO
Posterior spinal fusion for scoliosis was planned in a 14-year-old male patient with hemophilia B. Preoperative examination showed factor IX activity of 8.4% with no inhibitor development. A perioperative dosage schedule was prepared after examining the pharmacokinetics of recombinant coagulation factor IX in order to maintain levels of perioperative factor IX activity at < or = 80% for the first 6 days (days 0-6), and > or = 40% for days 7-14 postoperatively. The dose of recombinant coagulation factor IX was adjusted to maintain factor IX activity above 80%, while measuring coagulation activity every hour during the surgery. The patient showed a favorable course without hemorrhagic tendency. We could safely manage anesthesia without requiring allogeneic blood transfusion.